CompaniesAdocia

Adocia

active

Lyon, France

Founded 2005

Website

About

Molecular Delivery System for Therapeutic Proteins

Areas of Focus

Categories

Biologics & BiopharmaceuticalDrug Delivery & FormulationAntibody

Clinical Trials (29)

View all

Total Trials

As Lead Sponsor

As Collaborator

Total Enrollment

1,404

By Phase

PHASE1: 22PHASE2: 2PHASE1/PHASE2: 4PHASE3: 1

By Status

COMPLETED: 28UNKNOWN: 1

Clinical Trials Pipeline29 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

Today

NCT01098357

Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer

Phase: Phase 1/2

Role: Collaborator

Start: Jun 30, 2010

Completion: Sep 30, 2011

NCT01638325

A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 31, 2012

Completion: Sep 30, 2012

NCT01981031

A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2013

Completion: Aug 31, 2014

NCT02029924

A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 31, 2013

Completion: Aug 31, 2014

NCT02146651

A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes

Phase: Phase 2

Role: Lead Sponsor

Start: May 31, 2014

Completion: Dec 31, 2014

NCT02213146

A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

Phase: Phase 1/2

Role: Lead Sponsor

Start: Aug 31, 2014

Completion: Jun 30, 2015

NCT02236793

A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 31, 2014

Completion: Aug 31, 2016

NCT02344992

Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 31, 2015

Completion: Jun 30, 2015

NCT02514850

A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 31, 2015

Completion: Nov 30, 2015

NCT02514954

Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 31, 2015

Completion: Nov 30, 2015

NCT02528396

To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2015

Completion: Dec 31, 2015

NCT02529293

A Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product and U-200 Product in Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2015

Completion: Nov 30, 2015

NCT02562313

A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2015

Completion: Nov 30, 2016

NCT02562326

A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2015

Completion: Jan 31, 2016

NCT02660502

An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 31, 2016

Completion: May 31, 2016

NCT02739906

A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM

Phase: Phase 1/2

Role: Lead Sponsor

Start: Apr 30, 2016

Completion: Aug 31, 2016

NCT02915250

A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2016

Completion: Jun 30, 2017

NCT03176524

A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 6, 2017

Completion: Sep 4, 2017

NCT03180710

A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 6, 2017

Completion: Dec 21, 2017

NCT03179332

A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 20, 2017

Completion: Sep 27, 2017

NCT03512236

A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 25, 2018

Completion: Feb 14, 2019

NCT03916640

A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 4, 2019

Completion: Mar 1, 2019

NCT03981627

A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jun 6, 2019

Completion: Jun 27, 2020

NCT04501107

A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 3, 2020

Completion: Nov 3, 2020

NCT04816890

A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 23, 2021

Completion: Feb 24, 2022

NCT04972175

Safety and Efficacy of BC LisPram

Phase: Phase 1

Role: Collaborator

Start: Jul 28, 2021

Completion: Jun 30, 2022

NCT05373186

A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: May 12, 2022

Completion: Dec 4, 2022

NCT05373199

A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes

Phase: Phase 1

Role: Lead Sponsor

Start: May 12, 2022

Completion: Oct 28, 2022

NCT05373212

A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes